We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
Read MoreHide Full Article
Key Takeaways
ADMA's Q3 EPS met estimates while revenues rose 12% year over year to $134.2 million.
Asceniv drove record utilization and boosted gross margin to 56.3% from 49.8%.
ADMA raised 2025-26 revenue targets and advanced SG-001 toward potential FDA acceleration.
ADMA Biologics (ADMA - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of 16 cents, which were in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported adjusted EPS of 15 cents.
Revenues of $134.2 million (up 12% year over year) beat the Zacks Consensus Estimate of $130 million.
However, the stock was down 2.9% in after-market trading following the announcement. Year to date, shares of ADMA have lost 12.9% against the industry’s growth of 10.3%.
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’s Growth in Q3
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. It is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. The product is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Asceniv achieved record utilization during the quarter, driven by strong prescriber adoption and growing patient demand.
Gross margin improved to 56.3% from 49.8%, driven by a favorable mix of higher-margin immunoglobulin (IG) sales and operational efficiencies that reduced manufacturing costs.
Research & Development expenses skyrocketed to $1.5 million from $0.4 million in the year-ago quarter. Selling, general and administrative expenses increased 17.3% to $21.8 million.
ADMA received FDA lot release authorization for its first yield-enhanced commercial batches. These lots are expected to significantly improve manufacturing efficiency and drive gross margin expansion beginning in the fourth quarter of 2025, with continued gains through 2026 and beyond.
However, ADMA stated that year-over-year net income growth was tempered by a higher effective tax rate and temporary competitive dynamics in standard IVIG markets, mainly impacting Bivigam.
ADMA Biologics Inc Price, Consensus and EPS Surprise
ADMA now expects revenues of more than $510 million in 2025 (previous guidance: $500 million) and $630 million (previous guidance: $625 million) in 2026. Net income is now projected to exceed $158 million (previous guidance: $175 million) in 2025 due to a higher effective tax rate. Net income is now projected to exceed $255 million (previous guidance: $245 million) in 2026.
ADMA is in active negotiations to onboard additional distribution partners over the coming quarters, which would, if successful, broaden both Bivigam and Asceniv’s reach and support continued growth.
ADMA’s Progress With Another Candidate
ADMA continues to advance SG-001, a hyperimmune globulin targeting S. pneumonia.
A CNPV application has been submitted, and if accepted, could accelerate FDA review by two quarters or more. SG-001 demonstrated preclinical efficacy, and if successfully advanced to market, it could represent an approximately $300-$500 million annual high-margin opportunity protected through at least 2037.
Other Updates From ADMA
ADMA expects constructive 2026 payer negotiations to expand coverage next year, further supporting growth.
Alkermes’ EPS estimates for 2025 have increased to $1.96 from $1.82, while those for 2026 have risen from $1.70 to $1.77 in the past 30 days. The stock has gained nearly 7.9% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 4.58%.
In the past 60 days, estimates for Amicus Therapeutics’ 2025 EPS have remained constant at 31 cents. During the same time, EPS estimates for 2026 have increased from 69 cents to 70 cents. Year to date, shares of FOLD have lost 2.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
Key Takeaways
ADMA Biologics (ADMA - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of 16 cents, which were in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported adjusted EPS of 15 cents.
Revenues of $134.2 million (up 12% year over year) beat the Zacks Consensus Estimate of $130 million.
However, the stock was down 2.9% in after-market trading following the announcement. Year to date, shares of ADMA have lost 12.9% against the industry’s growth of 10.3%.
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’s Growth in Q3
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. It is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. The product is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Asceniv achieved record utilization during the quarter, driven by strong prescriber adoption and growing patient demand.
Gross margin improved to 56.3% from 49.8%, driven by a favorable mix of higher-margin immunoglobulin (IG) sales and operational efficiencies that reduced manufacturing costs.
Research & Development expenses skyrocketed to $1.5 million from $0.4 million in the year-ago quarter. Selling, general and administrative expenses increased 17.3% to $21.8 million.
ADMA received FDA lot release authorization for its first yield-enhanced commercial batches. These lots are expected to significantly improve manufacturing efficiency and drive gross margin expansion beginning in the fourth quarter of 2025, with continued gains through 2026 and beyond.
However, ADMA stated that year-over-year net income growth was tempered by a higher effective tax rate and temporary competitive dynamics in standard IVIG markets, mainly impacting Bivigam.
ADMA Biologics Inc Price, Consensus and EPS Surprise
ADMA Biologics Inc price-consensus-eps-surprise-chart | ADMA Biologics Inc Quote
ADMA Updates 2025 Guidance
ADMA now expects revenues of more than $510 million in 2025 (previous guidance: $500 million) and $630 million (previous guidance: $625 million) in 2026. Net income is now projected to exceed $158 million (previous guidance: $175 million) in 2025 due to a higher effective tax rate. Net income is now projected to exceed $255 million (previous guidance: $245 million) in 2026.
ADMA is in active negotiations to onboard additional distribution partners over the coming quarters, which would, if successful, broaden both Bivigam and Asceniv’s reach and support continued growth.
ADMA’s Progress With Another Candidate
ADMA continues to advance SG-001, a hyperimmune globulin targeting S. pneumonia.
A CNPV application has been submitted, and if accepted, could accelerate FDA review by two quarters or more. SG-001 demonstrated preclinical efficacy, and if successfully advanced to market, it could represent an approximately $300-$500 million annual high-margin opportunity protected through at least 2037.
Other Updates From ADMA
ADMA expects constructive 2026 payer negotiations to expand coverage next year, further supporting growth.
ADMA’s Zacks Rank & Stocks to Consider
ADMA currently has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Alkermes (ALKS - Free Report) and Amicus Therapeutics (FOLD - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ EPS estimates for 2025 have increased to $1.96 from $1.82, while those for 2026 have risen from $1.70 to $1.77 in the past 30 days. The stock has gained nearly 7.9% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 4.58%.
In the past 60 days, estimates for Amicus Therapeutics’ 2025 EPS have remained constant at 31 cents. During the same time, EPS estimates for 2026 have increased from 69 cents to 70 cents. Year to date, shares of FOLD have lost 2.5%.